Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Does treatment with recombinant human erythropoietin affect the survival of anemic patients with cancer?

Nature Clinical Practice Oncology volume 2, pages 444–445 (2005)Cite this article

boxed-textBohlius J et al. (2005) Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst 97: 489–498

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Littlewood TJ et al. (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19: 2865–2874

    Article  CAS  Google Scholar 

  2. Leyland-Jones B ; BEST Investigators and Study Group (2003) Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncology 4: 459–460

    Article  Google Scholar 

  3. Henke M et al. (2003) Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362: 1255–1260

    Article  CAS  Google Scholar 

  4. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Oncologic Drugs Advisory Committee. Minutes of the Meeting of Tuesday, May 4, 2004. [http://www.fda.gov/OHRMS/DOCKETS/ac/04/transcripts/4037T2.DOC] (Accessed 24 June 2005)

Download references

Acknowledgements

The synopsis was written by Chloe Harman, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. hematology consultant, Mayo Clinic, Rochester, MN, USA

    David P Steensma

  2. member of the hematology consulting staff at the Mayo Clinic, Rochester, MN, USA

    Thomas E Witzig

Authors
  1. David P Steensma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas E Witzig
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David P Steensma.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Steensma, D., Witzig, T. Does treatment with recombinant human erythropoietin affect the survival of anemic patients with cancer?. Nat Rev Clin Oncol 2, 444–445 (2005). https://doi.org/10.1038/ncponc0283

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0283

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing